AKT1 and cancer: The upregulation of PD-L1 expression in TAMs can be orchestrated by miR-183-5p, a known cancer-related miRNA, via the PTEN/AKT/PD-L1 pathway, rendering it a potential predictive biomarker for immune checkpoint blockade (ICB) therapy [44].